Vilin Bio Med Limited is an India-based company engaged in the business of manufacturing and selling pharmaceutical products. The Company is engaged in the manufacturing of pharmaceutical formulations, such as oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets and capsules and nutritional food supplements. Its products include cardiovascular drugs, musculoskeletal drugs, antibiotic drugs, central nervous system drugs, alimentary system drugs, genitourinary tract drugs, respiratory system and anti-allergic drugs, anti-diabetic drugs, multi-vitamins, minerals and amino acids supplements, miscellaneous drugs, liquid orals and external preparations. Its cardiovascular drugs include ATORVOSTATIN + Aspirin Capsules, Dapagliflozin 10 milligrams (mg) tablets, Fluvastatin Tablets 40 mg, PRASUGREL 10 mg tablets, and Cilnidipine five mg tablets. Its external preparations include calamine lotion, ciprofloxacin, fluocinolone acetonide and others.
VILIN BIO MED LIMITED Financial Highlights
- Revenue: VILIN BIO MED LIMITED reported revenue of ₹42.26 crore in FY26 vs ₹15.28 crore in FY25. It showed an increase of 176.57% on a yearly basis.
- Operating Profit: VILIN BIO MED LIMITED reported an operating profit of ₹2.84 crore in FY26 vs ₹0.31 crore in FY25. It showed an increase of 816.13% on a year-on-year basis.
- Net Profit: VILIN BIO MED LIMITED reported a net profit of ₹1.93 crore in FY26 vs ₹0.22 crore in FY25. It showed an increase of 777.27% on a yearly basis.